1. France Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Cellectis S.A.

Cellectis S.A.

CLLS
Cellectis S.A.US flagNASDAQ Global Market
0.93
USD
-0.11
- -
93.23MMarket Cap
Cellectis S.A.
CLLS
(NASDAQ Global Market)

Recent

price

0.93

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
1.47
0.75
0.36
1.01
1.64
1.27
0.71
0.31
0.36
1.2
0.71
0.42
0.01
0.46
0.73
0.56
Revenue per Share
- -
-2.19
-1.45
-3.7
- -
-0.67
-1.91
-2.78
-1.93
-2.41
-1.91
-2.69
-2.33
-1.77
-0.41
-0.67
-0.65
Basic EPS, GAAP
- -
-1.23
-1.36
-1.3
1.93
-0.02
-1.32
-1.54
-1.79
-1.93
-2.93
-2.9
-1.97
-0.45
0.21
-0.43
-0.45
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
2.62
3.41
0.18
2.51
8.17
7.72
7.37
9.65
7.42
6.63
4.87
2.58
1.18
1.82
0.76
0.41
Book Value per Share
- -
-0.61
1.3
-0.12
2.47
8.14
7.68
7.33
9.62
7.39
6.6
4.82
2.57
1.17
1.8
0.75
0.4
Tangible Book Value per Share
- -
14
20
21
26
34
35
36
41
42
43
42
46
57
91
100
100
Basic Weighted Avg Shares
21
21
15
7
26
56
45
25
13
15
51
30
19
1
42
73
57
Sales/Revenue/Turnover
-73.82
-122.1
-175.13
-494.74
-24.25
-55.46
-150.2
-367.83
-825.47
-813.38
-82.87
-341.01
-467.72
-12,887.81
-143.48
-45.34
-102.52
Operating Margin (%)
2
- -
5
3
2
2
2
3
2
7
8
14
18
19
20
20
19
Depreciation Expense
-11
-31
-29
-77
- -
-23
-67
-99
-79
-102
-81
-114
-106
-101
-37
-68
-65
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-52.98
-149.06
-193.75
-1,033.23
0.09
-40.81
-150.1
-394.51
-618.12
-672.09
-158.79
-376.32
-553.64
-13,385.3
-88.57
-92.66
-115.45
Profit Margin (%)
31
44
25
-4
69
281
256
278
441
329
263
176
81
78
121
90
49
Working Capital
2
68
4
5
3
- -
- -
- -
1
47
100
90
63
71
78
79
76
LT Debt
50
37
71
3
72
288
275
284
450
355
309
236
126
85
131
76
41
Total Equity
- -
- -
- -
- -
-14.61
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
3.32
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
44.74
Return on Capital (%)
-19.26
-71.14
-54.17
-207.66
0.06
-12.62
-24.01
-36.96
-23.35
-28.19
-27.07
-45.22
-62.57
-99.73
-34.08
-65.33
-94.53
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
12
9
8
LT Borrowings
51
52
53
LT Finance Leases
28
26
24
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
100
101
101
Market Capitalization
486
319
302

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
236
205
184
Cash, Cash Equivalents & STI
209
186
167
Accounts Receivable, Net
14
5
5
Inventories
- -
- -
- -
Total Current Liabilities
146
134
135
Payables & Accruals
28
24
26
ST Debt
12
9
8
Deferred Revenue
97
93
91

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-6.72%
-18.06%
-42.07%
Free Cash Flow
510.33%
-119.59%
-324.25%
Net Income, GAAP
28.04%
9.85%
83.87%
Sales/Revenue/Turnover
544.22%
1,059.96%
75.76%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5
8
16
13
42
2025
11
17
35
10
73
2026
6
5
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.08
-0.28
-0.23
- -
-0.41
2025
-0.18
-0.24
0.01
-0.26
-0.67
2026
-0.18
-0.22
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
AVROBIO, Inc. (AVRO)
Prime Medicine, Inc. (PRME)
Chimeric Therapeutics Limited (CHMMF)
Sionna Therapeutics, Inc. (SION)
StemCell Institute Inc. (7096.T)
Arch Biopartners Inc. (ARCH.V)
Business
Cellectis S.A. (Nasdaq: CLLS; Euronext Growth: ALCLS) is a clinical-stage biopharmaceutical company focused on gene-edited allogeneic CAR T-cell immunotherapies for cancer using its proprietary TALEN gene-editing technology and PulseAgile electroporation system; core product candidates include lasme-cel (UCART22) for relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), eti-cel (UCART20x22) for relapsed/refractory non-Hodgkin lymphoma (r/r NHL), and earlier-stage UCARTs targeting hematologic malignancies such as acute myeloid leukemia; the company pioneered off-the-shelf allogeneic CAR T-cells from healthy donors, enabling scalable, standardized manufacturing distinct from patient-specific autologous therapies. Founded in 1999 and headquartered at 8 Rue de la Croix Jarry in Paris, France, with additional facilities in New York, New York, and Raleigh, North Carolina, Cellectis operates primarily in the United States and Europe, targeting patients with high unmet needs in oncology through clinical trials and strategic manufacturing sites for plasmids, mRNA, viral vectors, and GMP UCART production. Recent developments include positive Phase 1 data for lasme-cel showing 68% overall response rate (83% at recommended Phase 2 dose) and median overall survival of 14.8 months in MRD-negative responders, with pivotal Phase 2 interim analysis expected in Q4 2026 and BLA submission in 2028; encouraging eti-cel results with 86% ORR and 57% complete response rate in r/r NHL, full Phase 1 data due in 2026; a 2023 strategic collaboration and investment with AstraZeneca involving up to $140 million equity and joint R&D for 10 cell/gene therapy programs in oncology, immunology, and rare diseases, yielding $47 million by end-2024; ongoing Servier arbitration decision expected by December 15, 2025; and advancements in non-viral CssDNA templates and TALEB base editors presented at ESGCT 2025.

Company News

Company News APIChatGPT

  • globenewswire.com

    Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS

  • globenewswire.com

    Cellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G.

  • globenewswire.com

    Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R.

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS

  • globenewswire.com

    Monthly information on share capital and company voting rights

  • marketbeat.com

    Cellectis Unveils In Vivo Gene-Editing Plans for Severe Lipid Disorders

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS

  • defenseworld.net

    Cellectis S.A. (NASDAQ:CLLS) Stock Has Consensus Price Target of $5.46

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS

  • gurufocus.com

    CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law

  • businesswire.com

    CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law

  • globenewswire.com

    CLLS INVESTOR ALERT: Investigation of Cellectis S.A. Announced by Holzer & Holzer, LLC

  • businesswire.com

    Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

  • gurufocus.com

    Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced -- Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

  • gurufocus.com

    Cellectis S.A. (CLLS) Shareholders Who Lost Money -- Contact Law Offices of Howard G. Smith About Securities Fraud Investigation